JPH11508762A5 - - Google Patents

Info

Publication number
JPH11508762A5
JPH11508762A5 JP1996535139A JP53513996A JPH11508762A5 JP H11508762 A5 JPH11508762 A5 JP H11508762A5 JP 1996535139 A JP1996535139 A JP 1996535139A JP 53513996 A JP53513996 A JP 53513996A JP H11508762 A5 JPH11508762 A5 JP H11508762A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1996535139A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11508762A (ja
Filing date
Publication date
Priority claimed from US08/446,918 external-priority patent/US5705151A/en
Priority claimed from US08/580,806 external-priority patent/US5935568A/en
Application filed filed Critical
Publication of JPH11508762A publication Critical patent/JPH11508762A/ja
Publication of JPH11508762A5 publication Critical patent/JPH11508762A5/ja
Ceased legal-status Critical Current

Links

JP8535139A 1995-05-18 1996-05-20 エフェクタ細胞調節用遺伝子療法 Ceased JPH11508762A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/446,918 US5705151A (en) 1995-05-18 1995-05-18 Gene therapy for T cell regulation
US446,918 1995-05-18
US08/580,806 US5935568A (en) 1995-05-18 1995-12-29 Gene therapy for effector cell regulation
US580,806 1995-12-29
PCT/US1996/007432 WO1996036366A1 (en) 1995-05-18 1996-05-20 Gene therapy for effector cell regulation

Publications (2)

Publication Number Publication Date
JPH11508762A JPH11508762A (ja) 1999-08-03
JPH11508762A5 true JPH11508762A5 (2) 2004-07-08

Family

ID=27034800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8535139A Ceased JPH11508762A (ja) 1995-05-18 1996-05-20 エフェクタ細胞調節用遺伝子療法

Country Status (8)

Country Link
US (1) US5935568A (2)
EP (1) EP0850071A4 (2)
JP (1) JPH11508762A (2)
KR (1) KR19990014875A (2)
AU (1) AU704012B2 (2)
CA (1) CA2221305A1 (2)
MX (1) MX9708854A (2)
WO (1) WO1996036366A1 (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE69837706T2 (de) * 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
WO1999036433A2 (en) * 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
NZ505877A (en) * 1998-01-16 2002-10-25 Univ Johns Hopkins Oral delivery of nucleic acid vaccines by particulate complexes
IL138075A0 (en) * 1998-02-27 2001-10-31 Univ Pennsylvania Vaccines, immunotherapeutics and methods for using the same
AU765260B2 (en) * 1998-04-20 2003-09-11 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
DE69929432T2 (de) * 1998-04-22 2006-09-28 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
CA2333750A1 (en) * 1998-06-23 1999-12-29 Dale T. Umetsu Adjuvant therapy
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
CA2338184A1 (en) * 1998-08-13 2000-02-24 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
CA2345023A1 (en) * 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
EP1185627A2 (en) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
WO2004044155A2 (en) * 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2005023853A1 (ja) 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
US9375468B2 (en) * 2012-02-08 2016-06-28 Premune Ab Prevention of inflammatory disorders in domestic non-human mammals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL95742A (en) * 1989-09-19 2000-12-06 Innogenetics Nv Recombinant polypeptides and peptides nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
CA2078003C (en) * 1990-01-17 2006-11-21 David S. Terman Tumor killing effects of enterotoxins and related compounds
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0499003A1 (en) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy

Similar Documents

Publication Publication Date Title
JP2000500033A5 (2)
JP2000500228A5 (2)
JP2000500445A5 (2)
JP2000500327A5 (2)
JP2000500145A5 (2)
JP2000501955A5 (2)
JP2000500406A5 (2)
JP2000500361A5 (2)
JP2000500115A5 (2)
JP2000500322A5 (2)
JP2000500258A5 (2)
JP2000500342A5 (2)
JP2000500192A5 (2)
JP2000500112A5 (2)
JP2000500739A5 (2)
JP2000500226A5 (2)
JP2000500051A5 (2)
JP2000500407A5 (2)
JP2000500019A5 (2)
JP2000500125A5 (2)
JP2000500044A5 (2)
JP2000500346A5 (2)
JP2000500257A5 (2)
JPH11512383A5 (2)
JP2000500090A5 (2)